Hypothesis

Normal brain aging triggers a conserved transcriptional shift that reduces the energetic cost of maintaining mature neuronal identity, thereby preserving cell numbers while lowering metabolic demand. This shift is driven by persistent activation of the AMPK‑SIRT1‑FOXO axis in response to chronic NAD+ decline, leading to repression of synaptic‑gene programs and upregulation of proteostatic and dedifferentiation markers. The result is a "low‑power mode" that sustains neuronal survival but compromises plasticity and network synchrony.

Mechanistic Rationale

1. Energy sensing – Aging brains show diminished NAD+ levels and reduced mitochondrial oxidative phosphorylation, which activates AMPK and SIRT1. Both kinases deacetylate FOXO transcription factors, promoting expression of genes involved in autophagy, stress resistance, and, paradoxically, repression of neuronal maturation programs (e.g., Neurod2, Satb2).
2. Epigenetic locking – Sustained FOXO activity recruits histone deacetylases (HDACs) and the NuRD complex to promoters of identity‑defining genes, establishing a repressive chromatin state that resembles a less differentiated, fetal‑like transcriptional profile.
3. Synaptic downscaling – Concurrently, AMPK phosphorylation of synaptic scaffolding proteins (e.g., PSD‑95) reduces surface AMPA receptor stability, weakening excitatory transmission without triggering complement‑mediated pruning.
4. Protective outcome – By lowering ATP demand per neuron, this reprogramming delays catastrophic bioenergetic failure and delays overt cell loss, aligning with observations of minimal cortical neuron loss despite cognitive decline.

Testable Predictions

• Prediction 1: Pharmacological elevation of NAD+ (e.g., with NR or NMN) in aged mice will suppress FOXO‑mediated repression of neuronal identity genes and restore youthful cortical transcriptional profiles.
• Prediction 2: Conditional knockout of Foxo1 or Foxo3 in forebrain excitatory neurons will prevent the aging‑associated downregulation of Satb2 and Bcl11a (Ctip2) and maintain synaptic gene expression.
• Prediction 3: Acute inhibition of AMPK in aged slices will rapidly increase mEPSC frequency and amplitude, indicating reactivation of synaptic strength.
• Prediction 4: Chromatin immunoprecipitation sequencing (ChIP‑seq) for FOXO1/3 in aged cortex will show enriched binding at promoters of mature neuronal genes coincident with increased HDAC2 occupancy.

Experimental Approach

1. Mouse cohorts: Young (3 mo), aged (24 mo), and aged treated with NMN (400 mg/kg/day) for 8 weeks. Include Foxo1/3 cKO lines.
2. Readouts:
   • Single‑nucleus RNA‑seq to quantify identity‑gene vs dedifferentiation‑gene modules.
   • NAD+ metabolomics confirming rescue.
   • Patch‑clamp recordings from layer 2/3 pyramidal neurons to assess mEPSC properties.
   • ChIP‑seq for FOXO1/3 and HDAC2 on sorted NeuN+ nuclei.
3. Falsification: If NAD+ supplementation fails to reverse transcriptional dedifferentiation or if FOXO cKO does not preserve synaptic gene expression despite verified NAD+ restoration, the hypothesis is refuted.

Broader Implications

This model reframes age‑related cognitive decline as a reversible metabolic‑epigenetic adaptation rather than irreversible neuronal loss. It suggests that boosting cellular NAD+ or modulating FOXO activity could re‑engage youthful transcriptional programs, enhancing synaptic resilience without needing to replace lost cells.